Skip to main content

Table 4 The relationship of CASC16 polymorphisms with breast cancer according to the stratification analysis by age

From: The association of CASC16 variants with breast Cancer risk in a northwest Chinese female population

SNPModelGenotype> 50 years≤ 50 years
CaseControlOR (95% CI)pCaseControlOR (95% CI)p
rs3803662AlleleA486 (70.43%)464 (67.64%)1 458 (68.15%)448 (66.67%)1 
G204 (29.57%)222 (32.36%)0.88 (0.70–1.10)0.262214(31.85%)224(33.33%)0.93 (0.74–1.17)0.561
CodominantA/A169 (48.99%)151 (44.02%)1 149 (44.34%)159 (47.32%)1 
A/G148 (42.90%)162 (47.23%)0.82 (0.60–1.12)0.202160 (47.62%)130 (38.69%)1.31 (0.95–1.81)0.097
G/G28 (8.12%)30 (8.75%)0.83 (0.48–1.46)0.52627 (8.04%)47 (13.99%)0.61 (0.36–1.03)0.063
DominantA/A169 (48.99%)151 (44.02%)1 149 (44.34%)159 (47.32%)1 
A/G-G/G176 (51.01%)192 (55.98%)0.82 (0.61–1.11)0.191187 (55.65%)177 (52.68%)1.13 (0.83–1.53)0.443
RecessiveA/A-A/G317 (91.88%)313 (91.25%)1 309 (91.96%)289 (86.01%)1 
G/G28(8.12%)30(8.75%)0.92 (0.54–1.58)0.76827 (8.04%)47 (13.99%)0.53 (0.32–0.88)0.014
Log-additive0.87 (0.69–1.10)0.2490.93 (0.74–1.17)0.553
rs4784227AlleleC489 (71.28%)531 (77.63%)1 487 (73.34%)497 (74.62%)1 
T197 (28.72%)153 (22.37%)1.34 (1.10–1.79)0.007177 (26.66%)169 (25.38%)1.07 (0.84–1.37)0.594
CodominantC/C171 (49.85%)205 (59.94%)1 182 (54.82%)189 (56.76%)1 
T/C147 (42.86%)121 (35.38%)1.46 (1.06–1.99)0.019123 (37.05%)119 (35.74%)1.07 (0.78–1.49)0.665
T/T25 (7.29%)16 (4.68%)1.88 (0.97–3.64)0.06127 (8.13%)25 (7.51%)1.13 (0.63–2.03)0.678
DominantC/C171 (49.85%)205 (59.94%)1 182 (54.82%)189 (56.76%)1 
T/C-T/T172 (50.14)137 (40.06%)1.51 (1.11–2.04)0.008150 (45.18%)144 (43.24%)1.08 (0.80–1.47)0.606
RecessiveC/C-T/C318 (92.71%)326 (95.32%)1 305 (91.87%)308 (92.49%)1 
T/T25 (7.29%)16 (4.68%)1.61 (0.84–3.07)0.15127 (8.13%)25 (7.51%)1.10 (0.62–1.94)0.743
Log-additive1.42 (1.10–1.82)0.0061.07 (0.84–1.36)0.589
rs45544231AlleleG569 (82.46%)563 (81.83%)1 525 (78.13%)534 (79.46%)1 
C121 (17.54%)125 (18.17%)0.96 (0.73–1.26)0.759147 (21.88%)138 (20.54%)1.08 (0.83–1.41)0.548
CodominantG/G239 (69.27%)230 (66.86%)1 206 (61.31%)216 (64.29%)1 
G/C91 (26.38%)103 (29.94%)0.85 (0.61–1.19)0.341113 (33.63%)102 (30.36%)1.16 (0.83–1.61)0.377
C/C15 (4.35%)11 (3.20%)1.31 (0.59–2.92)0.50417 (5.06%)18 (5.36%)0.98 (0.49–1.96)0.964
DominantG/G239 (69.27%)230 (66.86%)1 206 (61.31%)216 (64.29%)1 
G/C-C/C106 (30.72%)114 (33.14%)0.89 (0.65–1.23)0.49613 (38.69%)120 (35.71%)1.13 (0.83–1.55)0.433
RecessiveG/G-G/C330 (95.65%)333 (96.80%)1 31 (94.94%)318 (94.64%)1 
C/C15 (4.35%)11 (3.20%)1.34 (0.62–3.04)0.42917 (5.06%)18 (5.36%)0.94 (0.47–1.85)0.849
Log-additive0.96 (0.73–1.26)0.7631.08 (0.83–1.39)0.568
rs12922061AlleleC485 (70.29%)525 (76.31%)1 48 (72.77%)499 (74.26%)1 
T205 (29.71%)163 (23.69%)1.36 (1.07–1.73)0.01218 (27.23%)173 (25.74%)1.08 (0.85–1.38)0.537
CodominantC/C171(49.57%)200 (58.14%)1 17 (52.68%)181 (53.87%)1 
C/T143 (41.45%)125 (36.34%)1.34 (0.98–1.83)0.070135(40.18%)137 (40.77%)1.01 (0.74–1.38)0.953
T/T31 (8.99%)19 (5.52%)1.91 (1.04–3.51)0.03624 (7.14%)18 (5.36%)1.37 (0.72–2.61)0.340
DominantC/C171 (49.57%)200 (58.14%)1 177 (52.68%)181 (53.87%)1 
C/T-T/T174 (50.43%)144 (41.86%)1.41 (1.05–1.91)0.024159 (47.32%)155 (46.13%)1.05 (0.78–1.42)0.747
RecessiveC/C-C/T314 (91.01%)325 (94.48%)1 312 (92.86%)318 (94.64%)1 
T/T31 (8.99%)19 (5.52%)1.69 (0.94–3.06)0.08224 (7.14%)18 (5.36%)1.36 (0.73–2.56)0.335
Log-additive1.36 (1.07–1.73)0.0121.09 (0.85–1.39)0.518
rs3112612AlleleA569 (82.46%)562(81.69%)1 523 (78.06%)533 (79.32%)1 
G121(17.54%)126(18.31%)0.95 (0.72–1.25)0.707147 (21.94%)139 (20.68%)1.08 (0.83–1.40)0.574
CodominantA/A239 (69.28%)230 (66.86%)1 205 (61.19%)216 (64.29%)1 
A/G91 (26.38%)102 (29.65%)0.86 (0.61–1.20)0.372113 (33.73%)101 (30.06%)1.18 (0.85–1.64)0.331
G/G15 (4.35%)12 (3.49%)1.20 (0.55–2.63)0.64117 (5.07%)19 (5.65%)0.94 (0.47–1.85)0.848
DominantA/A239 (69.28%)230 (66.86%)1 205 (61.19%)216 (64.29%)1 
A/G-G/G106 (30.72%)114 (33.14%)0.89 (0.65–1.23)0.496130 (38.81%)120 (35.71%)1.14 (0.83–1.56)0.415
RecessiveA/A-A/G330 (95.65%)332 (96.51%)1 318 (94.93%)317 (94.35%)1 
G/G15 (4.35%)12 (3.49%)1.26 (0.58–2.73)0.56017 (5.07%)19 (5.65%)0.88 (0.45–1.74)0.722
Log-additive0.95 (0.73–1.24)0.7131.07 (0.83–1.38)0.596
  1. CI confidence interval, OR odds ratio, SNP single nucleotide polymorphism
  2. p values were calculated by unconditional logistic regression adjusted by age; p < 0.05 indicates statistical significance
  3. Highlighted in bold indicates the significant association between SNPs and breast cancer risk